Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Europe Kidney Cancer Drugs Market by Type (Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Transitional Cell Carcinoma, Wilms Tumor (Nephroblastoma), Renal Sarcoma, Angiomyolipoma, Oncocytoma, Others), by Drug Class (Monoclonal Antibodies, mTOR Inhibitors, Immune Checkpoint Inhibitor, Combined Therapies, Interleukin-2, Alpha-Interferon, Others) and by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03828

Pages: NA

Charts: NA

Tables: NA

Kidney cancer is a disease in which kidney cells become malignant and grow out of control, forming a tumor. The symptoms of renal cancer include blood in the urine, getting lumps or mass in sides or abdomen, weight loss, lethargy, and fever. The kidney cancer drug is normally given to patients who have reached stage four renal cell carcinoma.

Factors such as increasing incidences of kidney cancers due to reduced activity & sedentary lifestyle, growing geriatric population, and rise in cigarette smoking cases are the major factors that drive the market. However, high prices of branded drugs and side-effects associated with these drugs may hamper the growth of the kidney cancer drug market. Increase in R&D investments and introduction of novel molecules for drug delivery may boost the market opportunities in future.

The European kidney cancer drug market is segmented on the basis of product type, brand, and countries. Based on type, it is segmented into angiogenesis inhibitors, immunotherapies, monoclonal antibodies (mAbs), mTOR inhibitors, generics, and other products. On the basis of brand, the kidney cancer drug market is segmented into Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient (Pazopanib), and others. Geographically the market has been analyzed across Germany, UK, France, Italy, Spain, and rest of Europe.

The major players in the kidney cancer drug market are F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Onyx Pharmaceuticals Inc., Bayer AG, Active Biotech AB, Novartis AG, Amgen, Genentech, Inc., Cipla Limited, and Pfizer Inc.

Key Benefits

  • The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate imminent investment pockets.
  • Extensive analysis of the market has been conducted by following key product positioning and monitoring the top competitors within the market framework.
  • It offers a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on prevailing market opportunities.
  • Key players have been profiled and their strategies thoroughly analyzed to understand the competitive outlook of the European market.
  • Comprehensive analysis of all countries in Europe has been provided that determines prevailing opportunities.

Europe Kidney Cancer Drugs Market Key Segment:

By Product Type

  • Angiogenesis Inhibitors
  • Immunotherapies
  • Monoclonal Antibodies (mAbs)
  • mTOR Inhibitors
  • Generics
  • Other Products

By Brand

  • Afinitor (Everolimus)
  • Avastin (Bevacizumab)
  • Inlyta (Axitinib)
  • Nexavar (Sorafenib)
  • Proleukin (Aldesleukin)
  • Sutent (Sunitinib)
  • Torisel (Temsirolimus)
  • Votrient (Pazopanib)
  • Others

By Country

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

 Key Market Segments

  • By Type
    • Renal Cell Carcinoma (RCC)
    • Papillary Renal Cell Carcinoma
    • Chromophobe Renal Cell Carcinoma
    • Unclassified Renal Cell Carcinoma
    • Transitional Cell Carcinoma
    • Wilms Tumor (Nephroblastoma)
    • Renal Sarcoma
    • Angiomyolipoma
    • Oncocytoma
    • Others
  • By Drug Class
    • Monoclonal Antibodies
    • mTOR Inhibitors
    • Immune Checkpoint Inhibitor
    • Combined Therapies
    • Interleukin-2
    • Alpha-Interferon
    • Others
  • By Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • By Region
    • North America
    • Europe
    • Asia-Pacific
    • LAMEA

 
Key Market Players

  • Sanofi
  • GlaxoSmithKline
  • Astellas Pharma
  • Roche
  • Merck & Co
  • Bayer
  • Novartis
  • Amgen
  • Johnson & Johnson
  • Pfizer

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: EUROPE KIDNEY CANCER DRUGS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Renal Cell Carcinoma (RCC)

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Papillary Renal Cell Carcinoma

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Chromophobe Renal Cell Carcinoma

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Unclassified Renal Cell Carcinoma

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Transitional Cell Carcinoma

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Wilms Tumor (Nephroblastoma)

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Renal Sarcoma

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Angiomyolipoma

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. Oncocytoma

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

    • 4.11. Others

      • 4.11.1. Key Market Trends, Growth Factors and Opportunities

      • 4.11.2. Market Size and Forecast, By Region

      • 4.11.3. Market Share Analysis, By Country

  • CHAPTER 5: EUROPE KIDNEY CANCER DRUGS MARKET, BY DRUG CLASS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Drug Class

    • 5.2. Monoclonal Antibodies

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. MTOR Inhibitors

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Immune Checkpoint Inhibitor

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Combined Therapies

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Interleukin-2

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Alpha-Interferon

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Others

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

  • CHAPTER 6: EUROPE KIDNEY CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Online Pharmacy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Retail Pharmacy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: EUROPE KIDNEY CANCER DRUGS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Type

      • 7.2.3. Market Size and Forecast, By Drug Class

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S.

        • 7.2.6.1 Market size and forecast, type

        • 7.2.6.2 Market size and forecast, drug class

        • 7.2.6.3 Market size and forecast, distribution channel

      • 7.2.7. Canada

        • 7.2.7.1 Market size and forecast, type

        • 7.2.7.2 Market size and forecast, drug class

        • 7.2.7.3 Market size and forecast, distribution channel

      • 7.2.8. Mexico

        • 7.2.8.1 Market size and forecast, type

        • 7.2.8.2 Market size and forecast, drug class

        • 7.2.8.3 Market size and forecast, distribution channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Type

      • 7.3.3. Market Size and Forecast, By Drug Class

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France

        • 7.3.6.1 Market size and forecast, type

        • 7.3.6.2 Market size and forecast, drug class

        • 7.3.6.3 Market size and forecast, distribution channel

      • 7.3.7. Germany

        • 7.3.7.1 Market size and forecast, type

        • 7.3.7.2 Market size and forecast, drug class

        • 7.3.7.3 Market size and forecast, distribution channel

      • 7.3.8. Italy

        • 7.3.8.1 Market size and forecast, type

        • 7.3.8.2 Market size and forecast, drug class

        • 7.3.8.3 Market size and forecast, distribution channel

      • 7.3.9. Spain

        • 7.3.9.1 Market size and forecast, type

        • 7.3.9.2 Market size and forecast, drug class

        • 7.3.9.3 Market size and forecast, distribution channel

      • 7.3.10. UK

        • 7.3.10.1 Market size and forecast, type

        • 7.3.10.2 Market size and forecast, drug class

        • 7.3.10.3 Market size and forecast, distribution channel

      • 7.3.11. Russia

        • 7.3.11.1 Market size and forecast, type

        • 7.3.11.2 Market size and forecast, drug class

        • 7.3.11.3 Market size and forecast, distribution channel

      • 7.3.12. Rest Of Europe

        • 7.3.12.1 Market size and forecast, type

        • 7.3.12.2 Market size and forecast, drug class

        • 7.3.12.3 Market size and forecast, distribution channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Type

      • 7.4.3. Market Size and Forecast, By Drug Class

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China

        • 7.4.6.1 Market size and forecast, type

        • 7.4.6.2 Market size and forecast, drug class

        • 7.4.6.3 Market size and forecast, distribution channel

      • 7.4.7. Japan

        • 7.4.7.1 Market size and forecast, type

        • 7.4.7.2 Market size and forecast, drug class

        • 7.4.7.3 Market size and forecast, distribution channel

      • 7.4.8. India

        • 7.4.8.1 Market size and forecast, type

        • 7.4.8.2 Market size and forecast, drug class

        • 7.4.8.3 Market size and forecast, distribution channel

      • 7.4.9. South Korea

        • 7.4.9.1 Market size and forecast, type

        • 7.4.9.2 Market size and forecast, drug class

        • 7.4.9.3 Market size and forecast, distribution channel

      • 7.4.10. Australia

        • 7.4.10.1 Market size and forecast, type

        • 7.4.10.2 Market size and forecast, drug class

        • 7.4.10.3 Market size and forecast, distribution channel

      • 7.4.11. Thailand

        • 7.4.11.1 Market size and forecast, type

        • 7.4.11.2 Market size and forecast, drug class

        • 7.4.11.3 Market size and forecast, distribution channel

      • 7.4.12. Malaysia

        • 7.4.12.1 Market size and forecast, type

        • 7.4.12.2 Market size and forecast, drug class

        • 7.4.12.3 Market size and forecast, distribution channel

      • 7.4.13. Indonesia

        • 7.4.13.1 Market size and forecast, type

        • 7.4.13.2 Market size and forecast, drug class

        • 7.4.13.3 Market size and forecast, distribution channel

      • 7.4.14. Rest of Asia Pacific

        • 7.4.14.1 Market size and forecast, type

        • 7.4.14.2 Market size and forecast, drug class

        • 7.4.14.3 Market size and forecast, distribution channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Type

      • 7.5.3. Market Size and Forecast, By Drug Class

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil

        • 7.5.6.1 Market size and forecast, type

        • 7.5.6.2 Market size and forecast, drug class

        • 7.5.6.3 Market size and forecast, distribution channel

      • 7.5.7. South Africa

        • 7.5.7.1 Market size and forecast, type

        • 7.5.7.2 Market size and forecast, drug class

        • 7.5.7.3 Market size and forecast, distribution channel

      • 7.5.8. Saudi Arabia

        • 7.5.8.1 Market size and forecast, type

        • 7.5.8.2 Market size and forecast, drug class

        • 7.5.8.3 Market size and forecast, distribution channel

      • 7.5.9. UAE

        • 7.5.9.1 Market size and forecast, type

        • 7.5.9.2 Market size and forecast, drug class

        • 7.5.9.3 Market size and forecast, distribution channel

      • 7.5.10. Argentina

        • 7.5.10.1 Market size and forecast, type

        • 7.5.10.2 Market size and forecast, drug class

        • 7.5.10.3 Market size and forecast, distribution channel

      • 7.5.11. Rest of LAMEA

        • 7.5.11.1 Market size and forecast, type

        • 7.5.11.2 Market size and forecast, drug class

        • 7.5.11.3 Market size and forecast, distribution channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Bayer

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Novartis

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Astellas Pharma

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Roche

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Merck And Co

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Sanofi

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Johnson And Johnson

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. GlaxoSmithKline

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Pfizer

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Amgen

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL EUROPE KIDNEY CANCER DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. EUROPE KIDNEY CANCER DRUGS MARKET FOR RENAL CELL CARCINOMA (RCC), BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. EUROPE KIDNEY CANCER DRUGS MARKET FOR PAPILLARY RENAL CELL CARCINOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. EUROPE KIDNEY CANCER DRUGS MARKET FOR CHROMOPHOBE RENAL CELL CARCINOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. EUROPE KIDNEY CANCER DRUGS MARKET FOR UNCLASSIFIED RENAL CELL CARCINOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. EUROPE KIDNEY CANCER DRUGS MARKET FOR TRANSITIONAL CELL CARCINOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. EUROPE KIDNEY CANCER DRUGS MARKET FOR WILMS TUMOR (NEPHROBLASTOMA), BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. EUROPE KIDNEY CANCER DRUGS MARKET FOR RENAL SARCOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. EUROPE KIDNEY CANCER DRUGS MARKET FOR ANGIOMYOLIPOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. EUROPE KIDNEY CANCER DRUGS MARKET FOR ONCOCYTOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. EUROPE KIDNEY CANCER DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL EUROPE KIDNEY CANCER DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 13. EUROPE KIDNEY CANCER DRUGS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. EUROPE KIDNEY CANCER DRUGS MARKET FOR MTOR INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. EUROPE KIDNEY CANCER DRUGS MARKET FOR IMMUNE CHECKPOINT INHIBITOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. EUROPE KIDNEY CANCER DRUGS MARKET FOR COMBINED THERAPIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. EUROPE KIDNEY CANCER DRUGS MARKET FOR INTERLEUKIN-2, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. EUROPE KIDNEY CANCER DRUGS MARKET FOR ALPHA-INTERFERON, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE KIDNEY CANCER DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL EUROPE KIDNEY CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE KIDNEY CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE KIDNEY CANCER DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE KIDNEY CANCER DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE KIDNEY CANCER DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA EUROPE KIDNEY CANCER DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 29. U.S. EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. U.S. EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 31. U.S. EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. CANADA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. CANADA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 34. CANADA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE EUROPE KIDNEY CANCER DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ITALY EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. ITALY EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 50. ITALY EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. UK EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 55. UK EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 56. UK EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. RUSSIA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. RUSSIA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 59. RUSSIA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. REST OF EUROPE EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 61. REST OF EUROPE EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. ASIA-PACIFIC EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 64. ASIA-PACIFIC EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC EUROPE KIDNEY CANCER DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 67. CHINA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. CHINA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 69. CHINA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. JAPAN EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 72. JAPAN EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. INDIA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. INDIA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 75. INDIA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 76. SOUTH KOREA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 77. SOUTH KOREA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 78. SOUTH KOREA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. AUSTRALIA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 80. AUSTRALIA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 81. AUSTRALIA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. THAILAND EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 83. THAILAND EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 84. THAILAND EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. MALAYSIA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 86. MALAYSIA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 87. MALAYSIA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 88. INDONESIA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 89. INDONESIA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 90. INDONESIA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. REST OF ASIA PACIFIC EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 92. REST OF ASIA PACIFIC EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA PACIFIC EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 94. LAMEA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA EUROPE KIDNEY CANCER DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 98. BRAZIL EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 99. BRAZIL EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 101. SOUTH AFRICA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 102. SOUTH AFRICA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 103. SOUTH AFRICA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 104. SAUDI ARABIA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 105. SAUDI ARABIA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 107. UAE EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 108. UAE EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 109. UAE EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 110. ARGENTINA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 111. ARGENTINA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 112. ARGENTINA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 113. REST OF LAMEA EUROPE KIDNEY CANCER DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA EUROPE KIDNEY CANCER DRUGS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 115. REST OF LAMEA EUROPE KIDNEY CANCER DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 116. BAYER: KEY EXECUTIVES
  • TABLE 117. BAYER: COMPANY SNAPSHOT
  • TABLE 118. BAYER: OPERATING SEGMENTS
  • TABLE 119. BAYER: PRODUCT PORTFOLIO
  • TABLE 120. BAYER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. NOVARTIS: KEY EXECUTIVES
  • TABLE 122. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 123. NOVARTIS: OPERATING SEGMENTS
  • TABLE 124. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 125. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. ASTELLAS PHARMA: KEY EXECUTIVES
  • TABLE 127. ASTELLAS PHARMA: COMPANY SNAPSHOT
  • TABLE 128. ASTELLAS PHARMA: OPERATING SEGMENTS
  • TABLE 129. ASTELLAS PHARMA: PRODUCT PORTFOLIO
  • TABLE 130. ASTELLAS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. ROCHE: KEY EXECUTIVES
  • TABLE 132. ROCHE: COMPANY SNAPSHOT
  • TABLE 133. ROCHE: OPERATING SEGMENTS
  • TABLE 134. ROCHE: PRODUCT PORTFOLIO
  • TABLE 135. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. MERCK AND CO: KEY EXECUTIVES
  • TABLE 137. MERCK AND CO: COMPANY SNAPSHOT
  • TABLE 138. MERCK AND CO: OPERATING SEGMENTS
  • TABLE 139. MERCK AND CO: PRODUCT PORTFOLIO
  • TABLE 140. MERCK AND CO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. SANOFI: KEY EXECUTIVES
  • TABLE 142. SANOFI: COMPANY SNAPSHOT
  • TABLE 143. SANOFI: OPERATING SEGMENTS
  • TABLE 144. SANOFI: PRODUCT PORTFOLIO
  • TABLE 145. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 147. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 148. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 149. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 150. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. GLAXOSMITHKLINE: KEY EXECUTIVES
  • TABLE 152. GLAXOSMITHKLINE: COMPANY SNAPSHOT
  • TABLE 153. GLAXOSMITHKLINE: OPERATING SEGMENTS
  • TABLE 154. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
  • TABLE 155. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. PFIZER: KEY EXECUTIVES
  • TABLE 157. PFIZER: COMPANY SNAPSHOT
  • TABLE 158. PFIZER: OPERATING SEGMENTS
  • TABLE 159. PFIZER: PRODUCT PORTFOLIO
  • TABLE 160. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. AMGEN: KEY EXECUTIVES
  • TABLE 162. AMGEN: COMPANY SNAPSHOT
  • TABLE 163. AMGEN: OPERATING SEGMENTS
  • TABLE 164. AMGEN: PRODUCT PORTFOLIO
  • TABLE 165. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL EUROPE KIDNEY CANCER DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL EUROPE KIDNEY CANCER DRUGS MARKET
  • FIGURE 3. SEGMENTATION EUROPE KIDNEY CANCER DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN EUROPE KIDNEY CANCER DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALEUROPE KIDNEY CANCER DRUGS MARKET
  • FIGURE 11. EUROPE KIDNEY CANCER DRUGS MARKET SEGMENTATION, TYPE
  • FIGURE 12. EUROPE KIDNEY CANCER DRUGS MARKET FOR RENAL CELL CARCINOMA (RCC), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. EUROPE KIDNEY CANCER DRUGS MARKET FOR PAPILLARY RENAL CELL CARCINOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. EUROPE KIDNEY CANCER DRUGS MARKET FOR CHROMOPHOBE RENAL CELL CARCINOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. EUROPE KIDNEY CANCER DRUGS MARKET FOR UNCLASSIFIED RENAL CELL CARCINOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. EUROPE KIDNEY CANCER DRUGS MARKET FOR TRANSITIONAL CELL CARCINOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. EUROPE KIDNEY CANCER DRUGS MARKET FOR WILMS TUMOR (NEPHROBLASTOMA), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. EUROPE KIDNEY CANCER DRUGS MARKET FOR RENAL SARCOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. EUROPE KIDNEY CANCER DRUGS MARKET FOR ANGIOMYOLIPOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. EUROPE KIDNEY CANCER DRUGS MARKET FOR ONCOCYTOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. EUROPE KIDNEY CANCER DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. EUROPE KIDNEY CANCER DRUGS MARKET SEGMENTATION, DRUG CLASS
  • FIGURE 23. EUROPE KIDNEY CANCER DRUGS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. EUROPE KIDNEY CANCER DRUGS MARKET FOR MTOR INHIBITORS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. EUROPE KIDNEY CANCER DRUGS MARKET FOR IMMUNE CHECKPOINT INHIBITOR, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. EUROPE KIDNEY CANCER DRUGS MARKET FOR COMBINED THERAPIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. EUROPE KIDNEY CANCER DRUGS MARKET FOR INTERLEUKIN-2, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. EUROPE KIDNEY CANCER DRUGS MARKET FOR ALPHA-INTERFERON, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. EUROPE KIDNEY CANCER DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. EUROPE KIDNEY CANCER DRUGS MARKET SEGMENTATION, DISTRIBUTION CHANNEL
  • FIGURE 31. EUROPE KIDNEY CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 32. EUROPE KIDNEY CANCER DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 33. EUROPE KIDNEY CANCER DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 34. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 35. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 36. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 37. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 38. COMPETITIVE DASHBOARD
  • FIGURE 39. COMPETITIVE HEATMAP: EUROPE KIDNEY CANCER DRUGS MARKET
  • FIGURE 40. TOP PLAYER POSITIONING,2022
  • FIGURE 41. BAYER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. BAYER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. BAYER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. NOVARTIS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. NOVARTIS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. NOVARTIS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. ASTELLAS PHARMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. ASTELLAS PHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. ASTELLAS PHARMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. ROCHE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. ROCHE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. ROCHE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. MERCK AND CO: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. MERCK AND CO: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. MERCK AND CO: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. SANOFI: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. SANOFI: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. GLAXOSMITHKLINE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. GLAXOSMITHKLINE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. GLAXOSMITHKLINE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 65. PFIZER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. PFIZER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 67. PFIZER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 68. AMGEN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 69. AMGEN: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 70. AMGEN: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
Europe Kidney Cancer Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved